Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc. (RNAC) Q1 2025 Earnings

RNAC·Reported May 8, 2025·Before market open

Cartesian Therapeutics, Inc. reported Q1 2025 revenue of $1.1M (-81.2% YoY), beat analyst consensus of $687.5K by $412.5K. Diluted EPS came in at $-0.68 (+65.5% YoY), missed the $-0.61 consensus by $0.07.

Revenue
$1.1Mbeat by $412.5K
Consensus: $687.5K
Diluted EPS
$-0.68missed by $0.07
Consensus: $-0.61
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001453687-25-000085

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Cartesian Therapeutics, Inc.'s Q1 2025 earnings report.

Cartesian Therapeutics, Inc. (RNAC) reported Q1 2025 earnings on May 8, 2025 before market open.

Cartesian Therapeutics, Inc. reported revenue of $1.1M and diluted EPS of $-0.68 for Q1 2025.

Revenue beat the consensus estimate of $687.5K by $412.5K. EPS missed the consensus estimate of $-0.61 by $0.07.

Compared to the same quarter a year prior, revenue declined 81.2% from $5.8M a year earlier and diluted EPS grew 65.5% from $-1.97.

You can read the 10-Q periodic report (0001453687-25-000085) directly on SEC EDGAR. The filing index links above go to sec.gov.